The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | Sonrotoclax & zanubrutinib as frontline treatment for CLL: data from the BGB-11417-101 study
In this video, Chan Cheah, MBBS, FRACP, FRCPA, DMSc, Linear Clinical Research and Sir Charles Gairdner Hospital, Perth, Australia, discusses results from the BGB-11417-101 trial (NCT04277637), which is investigating the combination of sonrotoclax and zanubrutinib in patients with treatment-naïve chronic lymphocytic leukemia (CLL). Dr Cheah highlights the impressive measurable residual disease (MRD) clearance rates and encouraging preliminary progression-free survival (PFS) observed. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (AI generated)
Right, so the BGB-11417-101 trial is an ongoing study looking at the combination of sonrotoclax and zanubrutinib in patients with treatment-naive CLL. This cohort included – so sonrotoclax is a highly active BCL2 inhibitor. It’s essentially more potent than venetoclax, probably five-fold more potent at a similar dose, and in this study, we were treating patients with previously untreated CLL with a combination...
Right, so the BGB-11417-101 trial is an ongoing study looking at the combination of sonrotoclax and zanubrutinib in patients with treatment-naive CLL. This cohort included – so sonrotoclax is a highly active BCL2 inhibitor. It’s essentially more potent than venetoclax, probably five-fold more potent at a similar dose, and in this study, we were treating patients with previously untreated CLL with a combination. Probably the two main take-homes from this presentation were that the combination of S plus Z drives really impressive rates of undetectable MRD using sensitive assays, and I think in CLL it’s a little bit uncertain as to what the prognostic impact is of attaining MRD negativity, and we’re not entirely sure whether that’s going to translate to a PFS advantage, but it might, it does in some studies, and very encouraging preliminary PFS with only one event so far. So I think that’s really encouraging data for this combination, and there is, of course, an ongoing Phase III study, the 301 study, in which patients with treatment-naive CLL are being randomized to either S plus Z or an accepted standard of care, the CLL14 regimen of venetoclax and obinutuzumab, so we’re looking forward to the results of that.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Dizal: Consultancy, Honoraria; AstraZeneca: Consultancy, Honoraria, Membership on an entity’s Board of Directors or advisory committees, Other: Travel expenses, Speakers Bureau; Gilead: Consultancy, Honoraria, Membership on an entity’s Board of Directors or advisory committees, Speakers Bureau; Janssen: Consultancy, Honoraria, Membership on an entity’s Board of Directors or advisory committees, Speakers Bureau; BeiGene: Consultancy, Honoraria, Other: travel expenses, Speakers Bureau; Lilly: Consultancy, Honoraria, Membership on an entity’s Board of Directors or advisory committees, Research Funding; Roche: Consultancy, Honoraria, Membership on an entity’s Board of Directors or advisory committees, Other: Travel expenses, Research Funding, Speakers Bureau; AbbVie: Consultancy, Honoraria, Research Funding, Speakers Bureau; MSD: Consultancy, Honoraria, Membership on an entity’s Board of Directors or advisory committees, Research Funding; Menarini: Consultancy, Honoraria; Sobi: Consultancy, Honoraria; Regeneron: Consultancy, Honoraria; Genmab: Consultancy, Honoraria, Speakers Bureau; BMS: Consultancy, Honoraria, Research Funding.
